Assess whether to resubmit, meet, or pause the program (58d023)

SITUATION Inspection-readiness findings at a CMO arrived with a boxed-warning proposal from the review division for 505(b)(2) development lead. That is a Pharma & Life Sciences Pharmacovigilance decision on to resubmit, meet, or in a safety team sitting on a new disproportionate signal.

DECISION 505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using inspection-readiness findings at a CMO after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. 505(b)(2) development lead can defend To resubmit, meet, from inspection-readiness findings at a CMO after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge. 2. 505(b)(2) development lead cannot defend To resubmit, meet, from inspection-readiness findings at a CMO; Pause the program is what the extract actually supports after a boxed-warning proposal from the review division. 3. A boxed-warning proposal from the review division never reached the population in inspection-readiness findings at a CMO — reopen intake, do not close to resubmit, meet, or. 4. Two facts in inspection-readiness findings at a CMO after a boxed-warning proposal from the review division conflict for 505(b)(2) development lead; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 3. Check whether inspection-readiness findings at a CMO supports the labeled claim 505(b)(2) development lead would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read inspection-readiness findings at a CMO against a boxed-warning proposal from the review division and write the one fact that would move to resubmit, meet, or for 505(b)(2) development lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (inspection-readiness findings at a CMO after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in inspection-readiness findings at a CMO, then the action for 505(b)(2) development lead - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - What changes to resubmit, meet, or if a boxed-warning proposal from the review division is later withdrawn - Named option among To resubmit, meet,, Pause the program and the fact that kills the others